Comparative analysis of tumor content estimation methods based on simu- lated tumor samples identified their impact on somatic variant detection in cancer whole genome sequencing.


Journal

Biomedical research (Tokyo, Japan)
ISSN: 1880-313X
Titre abrégé: Biomed Res
Pays: Japan
ID NLM: 8100317

Informations de publication

Date de publication:
2023
Historique:
medline: 8 8 2023
pubmed: 7 8 2023
entrez: 6 8 2023
Statut: ppublish

Résumé

Whole genome sequencing (WGS) in cancer genomics has become widespread with recent technological innovations, and the amount and types of information obtained from WGS are increasing rapidly. Appropriate interpretation of results is becoming increasingly important in clinical applications. This study aimed to evaluate the accuracy of tumor content estimation and its impact on somatic variant detection, using 100 simulated tumor samples covering 10-100% tumor content constructed from the sequencing data of cell line models. Extensive analysis revealed that the estimation results varied among computational analytical methods. Notably, there was a large discrepancy in low tumor content (≤ 30%). The reproducibility decreased in cases wherein chromosome-scale copy number changes were observed in normal cells. The minimum tumor content required to detect somatic alterations was estimated to be 10-30%. Identification of whole genome doubling was achieved with the lowest tumor content, followed by single nucleotide variation/insertion or deletion, structural variation, and copy number variation. Tumor content had a significantly higher impact on the false negatives than the false positives in variant calls. Results should be interpreted cautiously for samples wherein tumor content is a concern. These results can form the basis of developing important guidelines for evaluating cancer WGS.

Identifiants

pubmed: 37544737
doi: 10.2220/biomedres.44.161
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

161-171

Auteurs

Takeshi Nagashima (T)

Cancer Diagnostic Research Division, Shizuoka Cancer Center Research Institute.
SRL Inc.

Kenichi Urakami (K)

Cancer Diagnostic Research Division, Shizuoka Cancer Center Research Institute.

Yuji Shimoda (Y)

Cancer Diagnostic Research Division, Shizuoka Cancer Center Research Institute.

Keiichi Ohshima (K)

Medical Genetics Division, Shizuoka Cancer Center Research Institute.

Masakuni Serizawa (M)

Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute.

Keiichi Hatakeyama (K)

Cancer Multiomics Division, Shizuoka Cancer Center Research Institute.

Sumiko Ohnami (S)

Cancer Diagnostic Research Division, Shizuoka Cancer Center Research Institute.

Shumpei Ohnami (S)

Cancer Diagnostic Research Division, Shizuoka Cancer Center Research Institute.

Akane Naruoka (A)

Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute.

Yasue Horiuchi (Y)

Cancer Diagnostic Research Division, Shizuoka Cancer Center Research Institute.

Akira Iizuka (A)

Immunotherapy Division, Shizuoka Cancer Center Research Institute.

Koji Maruyama (K)

Experimental Animal Facility, Shizuoka Cancer Center Research Institute.

Yasuto Akiyama (Y)

Immunotherapy Division, Shizuoka Cancer Center Research Institute.

Ken Yamaguchi (K)

Shizuoka Cancer Center.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH